Your Environment. Your Health.

Skip Navigation

Selected Publications

Environmental Cardiopulmonary Disease Group


Cytochrome P450

  1. Zeldin DC, Kobayashi J, Falck JR, Winder BS, Hammock BD, Snapper JR, JH Capdevila. Regio- and enantiofacial selectivity of epoxyeicosatrienoic acid hydration by cytosolic epoxide hydrolase. J Biol Chem. 1993 Mar 25;268(9):6402-6407.[Abstract ][PDF ]
  2. Zeldin DC, Wei S, Falck JR, Hammock BD, Snapper JR, Capdevila JH. Metabolism of epoxyeicosatrienoic acids by cytosolic epoxide hydrolase: substrate structural determinants of asymmetric catalysis. Arch Bioche Biophys. 1995 Jan 10;316(1)443-451.[Abstract ][PDF ]
  3. Zeldin DC, Plitman JD, Kobayashi J, Miller R, Philpot R, Snapper JR, Capdevila JH. The Rabbit pulmonary cytochrome P-450 arachidonic acid metabolic pathway: characterization and significance. J Clin Invest. 1995 May;95(5):2150-2160.[Abstract ][Full Text ][PDF ]
  4. Zeldin DC, Dubois RN, Falck JR, Capdevila JH. Molecular cloning, expression, and characterization of a human cytochrome P450 isoform that epoxidizes endogenous arachidonic acid pools. Arch Biochem Biophys. 1995 Sep 10;322(1):76-86.[Abstract ]
  5. Wu S, Moomaw C, Tomer KB, Falck JR, Zeldin DC. Molecular cloning and expression of CYP2J2, a human cytochrome P450 arachidonic acid epoxygenase highly expressed in heart. J Biol Chem. 1996 Feb 16;27(7):3460-3468.[Abstract ][Full Text ][PDF ]
  6. Zeldin DC, Moomaw C, Jesse N, Tomer K, Beetham J, Hammock BD, Wu S. Biochemical characterization of the human liver cytochrome P450 arachidonic acid metabolic pathway. Arch Biochem Biophys. 1996 Jun1;330(1):87-96.[Abstract ][PDF ]
  7. Zeldin DC, Foley J, Ma J, Boyle JE, Pascual JMS, Moomaw CR, Tomer KB, Steenbergen C, Wu S. CYP2J subfamily P450s in the lung: expression, localization, and potential functional significance. Mol Pharmacol. 1996 Nov;50(5):1111-1117.[Abstract ][PDF ]
  8. Zeldin DC, Foley J, Boyle JE, Moomaw CR, Tomer KB, Parker C, Steenbergen C, Wu S. Predominant expression of an arachidonate epoxygenase to islets of langerhans cells in human and rat pancreas: evidence for a role of epoxyeicosatrienoic acids in insulin, glucagon, and somatostatin secretion. Endocrinology. 1997 Mar;138(3):1338-1346.[Abstract ][Full Text ][PDF ]
  9. Wu S, Chen W, Murphy E, Gabel S, Tomer KB, Foley J, Steenbergen C, Falck JR, Moomaw C, Zeldin DC. Molecular cloning, expression, and functional significance of a cytochrome P450 highly expressed in rat heart myocytes. J Biol Chem. 1997 May 9;272(19):12551-12559.[Abstract ][Full Text ][PDF ]
  10. Zeldin DC, Foley J, Goldsworthy SM, Cook ME, Boyle JE, Ma J, Moomaw CR, Tomer KB, Steenbergen C, Wu S. CYP2J subfamily P450s in the gastrointestinal tract: expression, localization, and potential functional significance. Mol Pharmacol. 1997 Jun1;51(6):931-943.[Abstract ][Full Text ][PDF ]
  11. Ma J, Ramachandran S, Fiedorek FT, Zeldin DC. Mapping of the CYP2J genes to human chromosome 1 and mouse chromosome 4. Genomics. 1998 Apr 1;49(1):152-155.[Abstract ][PDF ]
  12. Pascual J, McKenzie A, Yankaskas J, Falck JR, Zeldin DC. Epoxygenase metabolites of arachidonic acid affect electrophysiologic properties of rat tracheal epithelial cells. J Pharmacol Exp Ther. 1998 Aug 1;286(2):772-7729.[Abstract ][Full Text ][PDF ]
  13. Luo G, Zeldin DC, Blaisdell JA, Hodgson E, Goldstein JA. Cloning and expression of murine CYP2Cs and their ability to metabolize arachidonic acid. Arch Biochem Biophys. 1998 Sep 1;357(1):45-57.[Abstract ][PDF ]
  14. Qu W, Rippe RA, Ma J, Scarborough PE, Biagini CP, Fiedorek FT, Travlos G, Parker C, Zeldin DC. Nutritional Status modulates rat liver p450 arachidonic acid metabolism. Mol Pharmacol. 1998 Sep 1;54(3):504-513.[Abstract ][Full Text ][PDF ]
  15. Chen J, Capdevila JH, Zeldin DC, Rosenberg RL. Inhibition of cardiac L-type calcium channels by epoxyeicosatrienoic acids. Mol Pharmacol. 1999 Feb 1;55(2):288-295.[Abstract ][Full Text ][PDF ]
  16. Scarborough PE, Ma J, Qu W, Zeldin DC. CYP2J subfamily P450 and their role in the bioactivation of arachidonic acid in extrahepatic tissues. Drug Met Rev. 1999 Feb;31(1):205-234.[Abstract ][Full Text ][PDF ]
  17. Ma J, Qu W, Scarborough PE, Tomer KB, Moomaw CR, Maronpot R, Davis LS, Breyer MD, Zeldin DC. Molecular cloning, enzymatic characterization, developmental expression, and cellular localization of a mouse cytochrome P450 highly expressed in kidney. J Biol Chem. 1999 Jun 18;274(25):17777-17788.[Abstract ][Full Text ][PDF ]
  18. Node K, Huo Y, Ruan L-L, Yang B, Splecker M, Ley K, Zeldin DC, Liao JK. Anti-inflammatory actions of epoxygenase-derived eicosanoids. Science. 1999 Aug;285(5431):1276-1279.[Abstract ][Full Text ][PDF ]
  19. Oleksiak MF, Wu S, Parker C, Karchner SI, Stegeman JJ, Zeldin DC. Identification, functional characterization and regulation of a new cytochrome P450 subfamily, the CYP2Ns. J Biol Chem. 2000 Jan 28;275(4):2312-2321.[Abstract ][Full Text ][PDF ]
  20. Yu Z, Huse LM, Ma J, Adler P, Graham L, Ma J, Zeldin DC, Kroetz DL. Increased CYP2J expression and epoxyeicosatrienoic acid formation in the spontaneously hypertensive rat kidney. Mol Pharmacol. 2000 May;57(5):1011-1020.[Abstract ][Full Text ][PDF ]
  21. Zeldin DC, Liao JK. Reply: Cytochrome P450-derived eicosanoids and the vascular wall. Trends Pharmacol Sci. 2000 Apr;21(4):127-128.[Abstract ][PDF ]
  22. Tsao C-C, Foley J, Coulter SJ, Maronpot R, Zeldin DC, Goldstein JA. CYP2C40, a Unique arachidonic acid 16-hydroxylase, is the major CYP2C isoform in the murine intestinal tract. Mol Pharmacol. 2000 Aug 1;58(2):279-287.[Abstract ][Full Text ][PDF ]
  23. Yu Z, Xu F, Huse LM, Morisseau C, Draper A, Newman JW, Parker C, Graham L, Engler M, Hammock BD, Zeldin DC, Kroetz DL. Soluble epoxide hydrolase regulates hydrolysis of vasoactive epoxyeicosatrienoic acids. Circ Res. 2000 Nov 24;87(11):992-998.[Abstract ][Full Text ][PDF ]
  24. Jacobs ER, Zeldin DC. The lung HETEs (and EETs) up. Am J Physiol. 2001 Jan;280(1): H1-H10.[Abstract ][Full Text ][PDF ]
  25. King LM, Ma J, Srettabunjong S, Li L, Graves J, Spiecker M, Liao JK, Mohrenweiser H, Zeldin DC. Cloning of the CYP2J2 gene and identification of functional polymorphisms. Mol Pharmacol. 2001 Apr 1;61(4): 840-852.[Abstract ][Full Text ][PDF ]
  26. Node K, Ruan X-L, Dai J, Yang S-X, Graham L, Zeldin DC, Liao JK. Activation of Gas mediates induction of tissue-type plasminogen activator gene transcription by epoxyeicosatrienoic acids. J Biol Chem. 2001 May 11;276(19):15983-15989.[Abstract ][Full Text ][PDF ]
  27. Qu W, Bradbury A, Tsao C-C, Maronpot R, Harry GJ, Davis L, Breyer MD, Waalkes M, Parker C, Falck JR, Chen J, Rosenberg R, Zeldin DC. Cytochrome P450 CYP2J9, a new mouse arachidonic acid ω-1 hydroxylase predominately expressed in brain. J Biol Chem. 2001 Jul 6;276(27):25467-25479.[Abstract ][Full Text ][PDF ]
  28. Yang B, Graham L, Falck JR, Liao JK, Zeldin DC. Overexpression of Cytochrome P450 CYP2J2 protects against hypoxia-reoxygenation injury in cultured bovine aortic endothelial cells. Mol Pharm. 2001 Aug 1;60(2):310-320.[Abstract ][Full Text ][PDF ]
  29. Zeldin DC. Epoxygenase pathways of arachidonic acid metabolism. J Biol Chem. 2001 Sep 28;276(39):36059-36062.[Abstract ][Full Text ][PDF ]
  30. Tsao C-C, Coulter SJ, Chien A, Maronpot R, Goldstein JA, Zeldin DC. Identification and distribution of five murine CYP2Cs in extrahepatic tissues and their stereoselectivity for arachidonic acid metabolism. J Pharmacol Exp Ther. 2001 Oct 1;299(1):39-47.[Abstract ][Full Text ][PDF ]
  31. Dai D, Zeldin DC, Blaisdell JA, Chanas B, Coulter SJ, Ghanayem BI, Goldstein JA. Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug Paclitaxel and arachidonic acid. Pharmacogenetics. 2001 Oct;11(7):597-607.[Abstract ]
  32. Sun J, Sui X, Bradbury JA, Zeldin DC, Conte MS, Liao JK. Inhibition of vascular smooth muscle cell migration by cytochrome P450 epoxygenase-derived eicosanoids. Circ Res. 2002 May 17;90(9):1020-1027.[Abstract ][Full Text ][PDF ]
  33. Kroetz DL, Zeldin DC. Cytochrome P450 pathways of arachidonic acid metabolism. Curr Opin Lipidol. 2002 June;13(3):273-278.[Abstract ]
  34. Ma J, Bradbury JA, King L, Maronpot R, Davis L, Breyer M, Zeldin DC. Molecular cloning and characterization of mouse CYP2J6, an unstable cytochrome P450 isoform. Biochem Pharmacol. 2002 Nov 15;64(10):1447-1460.[Abstract ][Full Text ]
  35. Zhao X, Pollock DM, Inscho EW, Zeldin DC, Imig JD. Decreased renal cytochrome P450 2C enzymes and impaired vasodilation are associated with angiotensin salt-sensitive hypertension. Hypertension. 2003 Mar 1;41(3):709-714.http://hyper.ahajournals.org/cgi/content/abstract/41/3/709[Abstract ][Full Text ][PDF ]
  36. Oleksiak MF, Wu S, Parker C, Qu W, Cox R, Zeldin DC, Stegeman JJ. Identification and regulation of a new vertebrate cytochrome P450 subfamily, the CYP2Ps, and functional characterization of CYP2P3, a conserved arachidonic acid epoxygenase/19-hydroxylase. Arch Biochem Biophys. 2003 Mar 15;411(2):223-234.[Abstract ][Full Text ][PDF ]
  37. Lee CR, Zeldin DC. The Reality of Pharmacogenomics: Optimizing therapeutic decision making. Environ Health Perspect. 2003 Aug;111(11):A566-A567.[Abstract ][PDF ]
  38. Przybyla-Zawislak BD, Srivasatva PK, Vazquez-Matias J, Moherenweiser HW, Maxwell J, Hammock BD, Bradbury JA, Enayetallah AE, Zeldin DC, Grant DL. Polymorphisms in human soluble epoxide hydrolase. Mol Pharmacol. 2003 Aug;64(2):482-490.[Abstract ][Full Text ][PDF ]
  39. Blackshear PJ, Graves J, Stumpo DJ, Cobos I, Rubenstein JL, Zeldin DC. Graded phenotypic response to partial and complete deficiency of a brain-specific variant of the winged helix transcription factor RFX4. Development. 2003 Oct 1;130(19):4539-4552.[Abstract ][Full Text ][PDF ]
  40. Zhao X, Pollock DM, Zeldin DC, Imig JD. Salt-sensitive hypertension after exposure to angiotensin is associated with inability to upregulate renal epoxygenases. Hypertension. 2003 Oct 1;42(4):775-780.[Abstract ][Full Text ][PDF ]
  41. Wang H, Lin L, Jiang J, Wang Y, Lu ZY, Bradbury JA, Lih FB, Wang DW, Zeldin DC. Up-regulation of endothelial nitric oxide synthase by endothelium-derived hyperpolarizing factor involves mitogen-activated protein kinase and protein kinase C signaling pathways. J Pharmacol Exp Ther. 2003 Nov;307(2):753-764.[Abstract ][Full Text ][PDF ]
  42. Yaghi A, Bradbury JA, Zeldin DC, Mehta S, Bend JR, McCormack DG. Pulmonary cytochrome P450 2J4 (CYP2J4) is reduced in a rat model of acute pseudomonas pneumonia. Am J Physiol Lung Cell Mol Physiol. 2003 Nov;285(5):L1099-1105.[Abstract ][Full Text ][PDF ]
  43. Zhao C, Wang P, Xiao X, Chao L, Wang DW, Zeldin DC. Gene therapy with human tissue kallikrein reduces hypertension and hyperinsulinemia in fructose-induced hypertensive rats. Hypertension. 2003 Nov 1;42(5):1026-1033.[Abstract ][Full Text ][PDF ]
  44. Pfister SL, Spitzbarth N, Zeldin DC, Lafite P, Mansuy D, Campbell WB. Rabbit aorta converts 15-HPETE to trihydroxyeicosatrienoic acids: potential role of cytochrome P450. Arch Biochem Biophys. 2003 Dec 1;420(1):142-152.[PDF ]
  45. Nelson DR, Zeldin DC, Hoffman S, Maltais L, Wain H, Nebert DW. Comparison of Cytochrome P450 (CYP) genes from the mouse and human genomes: nomenclature recommendations for genes, pseudogenes, and alternative-splice variants. Pharmacogenetics. 2004 Jan;14(1):1-18.[Abstract ]
  46. Yaghi A, Bend JR, Webb CD, Zeldin DC, Weicker S, Mehta S, McCormack DG. Excess nitric oxide decreases cytochrome P450 2J4 content and P450-dependent arachidonic acid metabolism in lung of rats with acute pneumonia. Am J Physiol Lung Cell Mol Physiol. 2004 Jun;286(6):L1260-L1267.[Abstract ][Full Text ][PDF ]
  47. Ma J, Graves J, Bradbury JA, Swope D, King L, Qu W, Clark J, Myers P, Walker V, Lindzey J, Korach K, Zeldin DC. Regulation of mouse renal CYP2J5 expression by sex hormones. Mol Pharmacol. 2004 Mar 1;65(3):730-743, 2004.[Abstract ][Full Text ][PDF ]
  48. Wang H, Zhao Y, Bradbury JA, Graves JP, Foley J, Blaisdell JA, Goldstein JA, Zeldin DC. Cloning, expression and characterization of three new mouse cytochrome P450 enzymes and partial characterization of their fatty acid oxidation activities. Mol Pharmacol. 2004 May;65(5):1148-1158.[Abstract ][Full Text ][PDF ]
  49. DeLozier TC, Tsao C-C, Coulter SJ, Foley J, Bradbury JA, Zeldin DC, Goldstein JA. CYP2C44, a new murine CYP2C that metabolizes arachidonic acid to unique stereospecific products. J Pharmacol Exp Ther. 2004 Sep;310(3):845-854.[Abstract ][Full Text ][PDF ]
  50. Seubert J, Yang B, Bradbury JA, Graves J, Miller L, Gabel S, Gooch R, Foley J, Newman JW, Mao L, Rockman HA, Hammock BD, Murphy E, Zeldin DC. Enhanced postischemic functional recovery in CYP2J2 Transgenic hearts involves mitochondrial ATP-sensitive K+ channels and p42/44 MAPK pathway. Circ Res. 2004 Sep 3;95(5):506-514.[Abstract ][Full Text ][PDF ]
  51. Xiao YF, Ke Q, Seubert JM, Bradbury JA, Graves J, Miller L, Falck JR, Krausz K, Gelboin HV, Morgan JP, Zeldin DC. Enhancement of cardiac L-type calcium currents in transgenic mice with cardiac-specific overexpression of CYP2J2. Mol Pharmacol. 2004 Dec;66(6):1607-1616.[Abstract ][Full Text ][PDF ]
  52. Speicker M, Darius H, Hankeln T, Soufi M, Sattler A, Schaefer JR, Node K, Borgel J, Mugge A, Lindpainter K, Huesing A, Maisch B, Zeldin DC, Liao JK. Risk of coronary artery disease associated with polymorphism of a cytochrome P450 epoxygenase, CYP2J2. Circulation. 2004 Oct 12;110(15):2131-2136.[Abstract ][Full Text ][PDF ]
  53. King LM, Gainer JV, David GL, Dai D, Goldstein JA, Brown NJ, Zeldin DC. Single nucleotide polymorphisms in the CYP2J2 and CYP2C8 genes and the risk of hypertension. Pharmacogenet Genomics. 2005 Jan;15(1):7-13.[Abstract ]
  54. Wang Y, Wei X, Xiao X, Hui R, Card JW, Carey MA, Wang DW, Zeldin DC. Arachidonic acid epoxygenase metabolites stimulate endothelial cell growth and angiogenesis involved in MAP kinase and PI3 kinase/Akt signaling pathways. J Pharmacol Exp Ther. 2005 Apr 19;314(2):522-532.[Abstract ][Full Text ][PDF ]
  55. Jiang JG, Chen CL, Card JW, Yang S, Chen JX, Fu XN, Ning YG, Xiao X, Zeldin DC, Wang DW. Cytochrome P450 2J2 promotes the neoplastic phenotype of carcinoma cells and is upregulated in human tumors. Cancer Res. 2005 Jun 1;65(11):4707-4715.[Abstract ][Full Text ][PDF ]
  56. Seubert JM, Graves JP, Collins JB, Sieber SO, Paules RS, Kroetz DL, Zeldin DC. Differential renal gene expression in pre-hypertensive and hypertensive spontaneously hypertensive rats. Am J Physiol Renal Physiol. 2005 Sep;289(3):F552-F561.[Abstract ][Full Text ][PDF ]
  57. Fornage M, Lee CR, Dorris PA, Bray MS, Heiss G, Zeldin DC, Boerwinkle E. The soluble epoxide hydrolase gene harbors sequence variation associated with susceptibility to and protection from incident ischemic stroke. Hum Mol Genet. 2005 Oct 1;14(19):2829-2837.[Abstract ][Full Text ][PDF ]
  58. Cotton RB, Sundell H, Zeldin DC, Morrow JD, Roberts LJ, Hazinski TA, Law AB, Steele S. Inhaled nitric oxide attenuates hyperoxic lung injury in lambs. Pediatr Res. 2006 Jan;59(1):142-146.
  59. Larsen BT, Miura H, Hatoum OA, Campbell WB, Hammock BD, Zeldin DC, Falck JR, Gutterman DD. Epoxyeicosatrienoic and dihydroxyeicosatrienoic acids dilate human coronary arterioles via BKCa channels: implications for soluble epoxide hydrolase inhibition. Am J Physiol Heart Circ Physiol. 2006 Feb;290(2):H491-H499.[Abstract ][Full Text ][PDF ]
  60. Lafite P, Dijols S, Buison D, Macherey AC, Zeldin DC, Dansette PM, Mansuy D. Design and synthesis of selective, high-affinity inhibitors of human P450 2J2. Bioorg Med Chem Lett. 2006 May 15;16(10):2777-2780.[Abstract ][Full Text ][PDF ]
  61. Lee CR, North KE, Bray MS, Fornage M, Seubert JM, Newman JW, Hammock BD, Couper DJ, Heiss G, Zeldin DC. Genetic variation in soluble epoxide hydrolase (EPHX2) and risk of coronary heart disease: The Atherosclerosis Risk in Communities (ARIC) Study. Hum Mol Genet. 2006 May 15;15(10):1640-1649.[Abstract ][Full Text ][PDF ]
  62. Paine MF, Hart HL, Lundington SS, Haining RL, Rettie AE, Zeldin D.C. The human intestinal cytochrome P450 Pie. Drug Metab Dispos. 2006 May;34(5):880-886.[Abstract ][Full Text ][PDF ]
  63. Cotton RB, Hazinski TA, Morrow JD, Roberts LJ, Zeldin DC, Lindstrom DP, Lappalainen U, Law AB, Steele S. Cimetidine does not prevent lung injury in newborn premature infants. Pediatr Res. 2006 Jun;59(6):795-800.[Abstract ][Full Text ][PDF ]
  64. Zhang D, Stumpo DJ, Graves JP, DeGraff LM, Grissom SF, Collins JB, Li L, Zeldin DC, Blackshear PJ. Identification of potential target genes for RFX4_v3, a transcription factor critical for brain development. J Neurochem. 2006 Aug;98(3):860-875.[Abstract ][Full Text ][PDF ]
  65. Lu T, Ye D, Wang X, Seubert J.M, Graves J, Bradbury JA, Zeldin DC, Lee HC. Cardiac and vascular KATP channels in rats are activated by endogenous epoxyeicosatrienoic acids through different mechanisms. J Physiol. 2006 Sep 1;575(Pt 2):627-644.[Abstract ][Full Text ][PDF ]
  66. Seubert JM, Sinal CJ, Graves JP, DeGraff LM, Bradbury JS, Lee CR, Goralski KB, Carey MA, Lauria A, Newman JW, Hammock BD, Falck JR, Roberts H, Rockman HA, Murphy E, Zeldin DC. Role of soluble epoxide hydrolase in postischemic recovery of heart contractile function. Circ Res. 2006 Aug 18;99(4):442-450.[Abstract ][Full Text ][PDF ]
  67. Gaedigk A, Baker D, Totah R, Gaedigk R, Pearce RE, Vyhlidal C, Zeldin DC, Leeder JS. Variability of CYP2J2 Expression in human fetal tissues. J Pharmacol Exp Ther. 2006 Nov;319(2):523-532.[Abstract ][Full Text ][PDF ]
  68. Lee CR, North KE, Bray MS, Avery CL, Mosher MJ, Couper DJ, Coresh J, Folsom AR, Boerwinkle E, Heiss G, Zeldin DC. NOS3 polymorphisms, cigarette smoking, and cardiovascular disease risk: The Atherosclerosis Risk in Communities (ARIC) study. Pharmacogenet Genomics. 2006 Dec;16(12):891-899.[Abstract ][Full Text ][PDF ]
  69. Wang MS, Saulter JY, Usuki E, Cheung YL, Hall M, Bridges AS, Loewen G, Parkinson OT, Stephens CE, Allen JL, Zeldin DC, Boykin DW, Tidwell RR, Parkinson A, Paine MF, Hall JE. CYP4F enzymes are the major enzymes in human liver microsomes that catalyze the O-demethylation of the antiparasitic prodrug DB289 [2,5-bis(4-amidinophenyl)furan-bis-O-methylamidoxime]. Drug Metab Dispos. 2006 Dec;34(12):1985-1994.[Abstract ][Full Text ][PDF ]
  70. Seubert JM, Zeldin DC, Nithipathikom K, Gross GJ. Role of epoxyeicosatrienoic acids in protecting the myocardium following isthemia/reperfusion injury. Prostaglandins Other Lipid Mediat. 2007 Jan;82(1-4):50-59.[Abstract ][Full Text ][PDF ]
  71. Lee CR, Bottone FG, Krahn J, Li L, Mohrenweiser H, Cook ME, Petrovich RM, Bell DA, Eling TE, Zeldin DC. Identification and functional characterization of polymorphisms in human cyclooxygenase-1 (PTGS1). Pharmacogenet Genomics. 2007 Feb;17(2):145-160.[Abstract ][Full Text ][PDF ]
  72. DeLozier T, Kissling GE, Coulter SJ, Dai D, Foley J, Bradbury JA, Murphy E, Steenbergen C, Zeldin DC, Goldstein JA. Detection of human CYP2C8, CYP2C9 and CYP2J2 cardiovascular tissues. Drug Metab Dispos. 2007 Apr;35(4):682-688.[Abstract ][Full Text ][PDF ]
  73. Lee CR, North KE, Bray MS, Couper DJ, Heiss G, Zeldin DC. CYP2J2 and CYP2C8 polymorphisms and coronary heart disease risk: the Atherosclerosis Risk in Communities (ARIC) study. Pharmacogenet Genomics. 2007 May;17(5):349-58.[Abstract ][Full Text ][PDF ]
  74. Yuan G, Deng J, Wang T, Zhao C, Xu X, Wang P, Voltz JW, Edin ML, Xiao X, Chao L, Chao J, Zhang XA, Zeldin DC, Wang DW. Tissue kallikrein reverses insulin resistance and attenuates nephropathy in diabetic rats by activation of phosphatidylinositol 3-kinase/protein kinase B and adenosine 5'-monophosphate-activated protein kinase signaling pathways. Endocrinology. 2007 May;148(5):2016-26.[Abstract ][Full Text ][PDF ]
  75. Jiang JG, Ning YG, Chen C, Ma D, Liu ZJ, Yang S, Zhou J, Xiao X, Zhang XA, Edin ML, Card JW, Wang J, Zeldin DC, Wang DW. Cytochrome P450 epoxygenase promotes human cancer metastasis. Cancer Res. 2007 Jul 15;67(14):6665-74.[Abstract ][Full Text ]
  76. Nüsing RM, Schweer H, Fleming I, Zeldin DC, Wegmann M. Epoxyeicosatrienoic acids affect electrolyte transport in renal tubular epithelial cells: Dependence on cyclooxygenase and cell polarity. Am J Physiol Renal Physiol. 2007 Jul;293(1):F288-98.[Abstract ][Full Text ][PDF ]
  77. Yang S, Lin L, Chen J-X, Lee CR, Seubert JM, Wang Y, Wang H, Chao Z-R, Tao D-D, Gong J-P, Lu Z-Y, Wang DW, Zeldin DC. Cytochrome P450 epoxygenases protect endothelial cells from apoptosis induced by tumor necrosis factor-α via MAPK and PI3K/Akt signaling pathways. AmericanJ Physiol Heart Circ Physiol. 2007 Jul;293(1)H142-51.[Abstract ][Full Text ]
  78. Lafite P, Dijols S, Zeldin DC, Dansette PM, Mansuy D. Selective, competitive, and mechanism-based inhibitors of human cytochrome P450 2J2. Arch Biochem Biophys. 2007 Aug 15;464(2):155-68.[Abstract ][Full Text ][PDF ]
  79. Nüsing RM, Schweer H, Fleming I. Zeldin DC, Wegmann M. Expoxyeicosatrienoic acids affect electrolyte transport in renal tubular epithelial cells: Dependence on cyclooxygenase and cell polarity. Am J Physiol Renal Physiol. 2007 Jul;293(1):F288-98.[Abstract ][Full Text ][PDF ]
  80. Lafite P, André F, Zeldin DC, Dansette PM, Mansuy D. Unusual regioselectivity and active site topology of human cytochrome P450 2J2. Biochemistry. 2007 Sep 11;46(36): 10237-47.[Abstract ][Full Text ][PDF ]
  81. Ke Q, Xiao Y-F, Bradvury JA, Graves JP, DeGraff LM, Seubert JM, Zeldin DC. Electrophysiological properties of cardiomyocytes isolated from CYP2J2 transgenic mice. Mol Pharmacol. 2007 Oct;72(4):11063-73.[Abstract ][Full Text ][PDF ]
  82. Wang MZ, Wu JQ, Bridges AS, Zeldin DC, Kornbluth S, Tidwell RR, Hall JE, Paine MF. Human enteric microsomal CYP4F enzymes O-demethylate the antiparasitic prodrug pafuramidine. Drug Metab Dispos. 2007 Nov;35(11):2067-75.[Abstract ][Full Text ][PDF ]
  83. Zhang D, Zeldin DC, Blackshear PJ. Regulatory factor X4 variant 3: A transcription factor involved in brain development and disease. J Neurosci Res. 2007 Dec;85(16): 3515-22.[Abstract ][Full Text ][PDF ]
  84. Lee CR, North KE, Bray MS, Couper DJ, Heiss G, Zeldin DC. Cyclooxygenase polymorphisms and risk of cardiovascular events: The Atherosclerosis Risk in Communities (ARIC) study. Clinical Pharmacol Ther. 2008 Jan;83(1):52-60.[Abstract ][Full Text ][PDF ]
  85. Zhang L, Ding H, Yan J, Hui R, Wang W, Kissling GE, Zeldin DC, Wang DW. Genetic variation in cytochrome P450 2J2 and soluble epoxide hydrolase and the risk of ischemic stroke in a chinese population. Pharmacogenet Genomics. 2008 Jan;18(1):45-51.[Abstract ][Full Text ][PDF ]
  86. Larsen BT, Gutterman DD, Sato A, Toyama K, Campbell WB, Zeldin DC, Falck JR, Miura H. Hydrogen peroxide inhibits cytochrome P450 epoxygenases: Interaction between two endothelium-derived hyperpolarizing factors. Circ Res. 2008 Jan 4;102(1):59-67.[Abstract ][Full Text ][PDF ]
  87. van Waterschoot RAB, van Herwaarden AE, Lagas JS, Sparidans RW, Wagenaar E, van der Kruijssen CMM, Goldstein JA, Zeldin DC, Beijnen JH, Schinkel AH. Midazolam Metabolism in Cytochrome P450 3A knockout mice can be attributed to upregulated CYP2C enzymes. Mol Pharmacol. 2008 Mar;73(3):1029-36.[Abstract ][Full Text ][PDF ]
  88. Zhang D, Harry JG, Blackshear PJ, Zeldin DC. G-protein pathway suppressor 2 (GPS2) interacts with the regulatory factor X4 variant 3 (RFX4_v3) and functions as a transcriptional co-activator. Journal Biol Chem. 2008 Mar 28;283(13):8580-90.[Abstract ][Full Text ]
  89. Tu L, Xu X, Wan H, Zhou C, Deng J, Xu G, Xiao W, Xiao X, Chen Y, Edin ML, Voltz JW, Zeldin DC, Wang DW. Delivery of recombinant adeno-associated virus-mediated human tissue kallikrein for therapy of chronic renal failure in rats. Hum Gene Ther. 2008 Apr;19(4):318-30.[Abstract ][Full Text ][PDF ]
  90. Moshal KS, Zeldin DC, Sithu SD, Sen U, Tyagi N, Kumar M, Hughes WM, Metreveli N, Rosenberger DSE, Singh M, Vacek TP, Rodriguez WE, Ayotunde A, Tyagi SC. Cytochrome P450 (CYP) 2J2 gene transfection attenuates MMP-9 via inhibition of NF-k(beta) in hyperhomocysteinemia. J Cell Physiol. 2008 Jun;215(3):771-81.[Abstract ][Full Text ][PDF ]
  91. Nayeem MA, Poloyac SM, Falck JR, Zeldin DC, Ledent C, Ponnoth DS, Ansari HR, Mustafa SJ. Role of CYP epoxygenases in A2A AR-mediated relaxation using A2A AR-null and wild-type mice. Am J Physiol Heart Circ Physiol. 2008 Nov;295(5):H2068-78.[Abstract ][Full Text ]
  92. Athirakul K, Bradbury JA, Graves JP, DeGraff LM, Ma J, Zhao Y, Couse JF, Quigley R, Harder DR, Zhao X, Imig JD, Pedersen TL, Newman JW, Hammock BD, Conley AJ, Korach KS, Coffman TM, Zeldin DC. Increased blood pressure in mice lacking a cytochrome P450 2J5. FASEB J. 2008 Dec;22(12):4096-108.[Abstract ][Full Text ]
  93. Guan H, Wang P, Hui R, Edin ML, Zeldin DC, Wang DW. Adeno-associated virus-mediated human C-reactive protein gene delivery causes endothelial dysfunction and hypertension in rats. Clin Chem. 2009 Feb;55(2):274-84.[Abstract ][Full Text ][PDF ]
  94. Zhao CX, Xu X, Cui Y, Wang P, Wei X, Yang S, Edin ML, Zeldin DC, Wang DW. Increased endothelial nitric-oxide synthase expression reduces hypertension and hyperinsulinemia in fructose-treated rats. J. Pharmacol. Exp. Ther. 2009 Feb;328(2):610-20.[Abstract ][Full Text ][PDF ]
  95. Nayeem M, Ponnoth D, Boegehold M, Zeldin DC, Falck JR, Mustafa SJ. High salt diet enhances mouse aortic relaxation through adenosine A2A receptor via CYP epoxygenases. Am J Physiol Regul Integr Comp Physiol. 2009 Mar;296(3):R567-74.[Abstract ][Full Text ]
  96. Homma S, Koido S, Sagawa Y, Suzuki H, Komita H, Nagasaki E, Takahara A, Horiguchi-Yamada J, Tajiri H, Zeldin DC, Obata T. Antigenic stimulation with cytochrome P450 2J expressed in mouse hepatocellular carcinoma cells regulates host anti-tumour immunity. Clin Exp Immunol. 2009 May;156(2):344-52.[Abstract ][Full Text ][PDF ]
  97. Iliff JJ, Wang R, Zeldin DC, Alkayed NJ. Epoxyeicosanoids as mediators of neurogenic vasodilation in cerebral vessels. Am J Physiol Heart Circ Physiol. 2009 May;296(5):H1352-63.[Abstract ][Full Text ]
  98. Bodiga S, Zhang R, Jacobs DE, Larsen BT, Tampo A, Manthati VL, Kwok WM, Zeldin DC, Falck JR, Gutterman DD, Jacobs ER, Medhora MM. Protective actions of epoxyeicosatrienoic acid: dual targeting of cardiovascular P1eK and KATP channels. J Mol Cell Cardiol. 2009 Jun;46(6):978-88.[Abstract ][Full Text ][PDF ]
  99. Chen C, Li G, Liao W, Wu J, Liu L, Ma D, Zhou J, Elbekai RH, Edin ML, Zeldin DC, Wang DW. Selective inhibitors of CYP2J2 related to terfenadine exhibit strong activity against human cancers in vitro and in vivo. J Pharmacol Exp Ther. 2009 Jun;329(3):908-18.[Abstract ][Full Text ][PDF ]
  100. Zhang Y, El-Sikhry H, Chaudhary K, Batchu SN, Shayeqanpour A, Jukar TO, Bradbury JA, Graves JP, DeGraff LM, Myers PH, Rouse DC, Foley J, Nyska A, Zeldin DC, Seubert JM. Overexpression of CYP2J2 provides protection against doxorubicin induced cardiotoxicity. Am J Physiol Heart Circ Physiol. 2009 Jul;297(1):H37-46.[Abstract ][Full Text ]
  101. Chaudhary KR, Batchu SN, Graves JP, Das D, Suresh MR, Zeldin DC, Seubert JS. Role of B-type natriuretic peptide in epoxyeicosatrienoic acid mediated improved postischemic recovery of heart contractile function. Cardiovasc Res. 2009 July 15;83(2):362-70.[Abstract ][Full Text ][PDF ]
  102. Wray JA, Sugden MC, Zeldin DC, Greenwood GK, Samsuddin S, DeGraff LM, Bradbury JA, Holness MJ, Warner TD, Bishop-Bailey D. The epoxygenases CYP2J2 activates the nuclear receptor PPARalpha; in vitro and in vivo. PLoS One. 2009 Oct 12;4(10):e7421.[Abstract ][Full Text ][PDF ]
  103. Baragatti B, Laniado-Schwartzman M, Angeloni D, Scebba F, Ciofini E, Sodini D, Ottaviano V, Nencioni S, Paolicchi A, Graves JP, Zeldin DC, Gotlinger K, Luin S, Coceani F. EDHF function in the ductus arteriosus: Evidence against involvement of epoxyeicosatrienoic acids (EETs) and 12S-hydroxyeicosatrienoic acid (12S-HETE). Am J Physiol Heart Circ Physiol. 2009 Dec;297(6):2161-8.[Abstract ][Full Text ][PDF ]
  104. Zheng C, Wang L, Li R, Ma B, Tu L, Xu X, Dackor RT, Zeldin DC, Wang DW. Gene delivery of a cytochrome P450 epoxygenase ameliorates monocrotaline-induced pulmonary artery hypertension in rats. Am J Respir Cell Mol Biol. 2010 Jan 29;[Abstract ][PDF ]
  105. Cheng LM, Jiang JG, Sun ZY, Chen C, Dackor RT, Zeldin DC, Wang DW. The epoxyeicosatrienoic acid-stimulated proliferation of EGF-R involves activation of metalloproteinases and release of HB-EGF in cancer cells. Acta Pharmacol Sin. 2010 Feb;31(2):211-18.[Abstract ][Full Text ][PDF ]
  106. Ding H, Cui G, Zhang L, Xu Y, Wu B, Wang Q, Hui R, Wang W, Dackor RT, Kissling GE, Zeldin DC, Wang DW. Association of common variants of CYP4A11 and CYP4F2 with stroke in the Han Chinese population. Pharmacogenet Genomics. 2010 Mar;20(3):187-94.[Abstract ]
  107. Kim DH, Vanella L, Inoue K, Burgess A, Gotlinger K, Manthati VL, Koduru SR, Zeldin DC, Falck JR, Schwartzman ML, Abraham NG. EET-agonist regulates mesenchymal stem cells-derived adipocytes through activation of HO-1-pAKT signaling and a decrease in PPARgamma. Stem Cells Dev. 2010 19(2):1863-1873.[Abstract ][PDF ]
  108. Xu X, Zhao CX, Wang L, Tu L, Fang X, Zheng C, Edin ML, Zeldin DC, Wang DW. Increased CYP2J3 expression reduces insulin resistance in fructose-treated rats and db/db mice. Diabetes. 2010 Apr;59(4):997-1005.[Abstract ][Full Text ][PDF ]
  109. Konno Y, Kamino H, Moore R, Lih F, Tomer KB, Zeldin DC, Goldstein JA, Negishi M. The nuclear receptors CAR and PXR activate the Cyp2c55 gene in mouse liver. Drug Metab Dispos. 2010 Jul;38(7):1177-82.[Abstract ][Full Text ][PDF ]
  110. Nayeem MA, Zeldin DC, Boegehold MA, Morisseau C, Marowsky A, Ponnoth DS, Roush KP, Falck JR. Modulation by salt intake of the vascular response mediated through adenosine A2A receptor: Role of CYP epoxygenase and soluble epoxide hydrolase. Am J Physiol Regul Integr Comp Physiol. 2010 Jul;299(1):R325-33.[Abstract ][Full Text ][PDF ]
  111. Xiao B, Yan J, Xiao X, Voltz JW, Zeldin DC, Wang DW. Overexpression of Cytochrome P450 Epoxygenases prevents development of hypertension in spontaneously hypertensive rats by enhancing atrial natriuretic peptide. J Pharmacol Exp Ther. 2010 Sep 10;334(3):784-94.[Abstract ][Full Text ][PDF ]
  112. Lee CR, Imig JD, Edin ML, Foley J, DeGraff LM, Bradbury JA, Graves JP, Lih FB, Clark J, Myers P, Perrow L, Lepp AN, Kannon A, Ronnekleiv OK, Alkayed NJ, Falck JR, Tomer KB, Zeldin DC. Endothelial expression of human cytochrome P450 epoxygenases lowers blood pressure and attenuates hypertension-induced renal injury in mice. FASEB J. 2010 Oct;24(8);[Abstract ][PDF ]
  113. Lee CR, Imig JD, Edin ML, Foley J, DeGraff LM, Bradbury JA, Graves JP, Lih FB, Clark J, Myers P, Perrow L, Lepp AN, Kannon MA, Ronnekleiv OK, Alkayed NJ, Falck JR, Tomer KB, Zeldin DC. Endothelial expression of human cytochrome P450 epoxygenases lowers blood pressure and attenuates hypertension-induced renal injury in mice. The FASEB journal. 2010 24(10):3770-81.[Abstract ][Full Text ][PDF ]
  114. Chen C, Wei X, Rao X, Wu J, Yang S, Chen F, Ma D, Zhou J, Dackor RT, Zeldin DC, Wang DW. CYP2J2 is highly expressed in hematologic malignant diseases and promotes tumor cell growth. The Journal of pharmacology and experimental therapeutics. 2011 336(2):344-355.[Abstract ][Full Text ][PDF ]
  115. Lee CR, Pretorius M, Schuck RN, Burch LH, Bartless J, Williams SM, Zeldin DC, Brown NJ. Genetic Variation in Soluble Epoxide Hydrolase (EPHX2) is Associated with Forearm Vasoodilator Responses in Humans. Hypertension. 2011 57(1):116-122.[Abstract ][Full Text ][PDF ]
  116. Deng Y, Edin ML, Theken KN, Schuck RN, Flake GP, Kannon MA, DeGraff LM, Lih FB, Foley J, Bradbury JA, Graves JP, Tomer KB, Falck JR, Zeldin DC, Lee CR. Endothelial CYP epoxygenase overexpression and soluble epoxide hydrolase disruption attenuate acute vascular inflammatory responses in mice. The FASEB journal. 2011 25(2):703-713.[Abstract ][Full Text ][PDF ]
  117. Nayeem MA, Zeldin DC, Boegehold MA, Falck JR. Salt modulates vascular response through adenosine A(2A) receptor in eNOS-null mice: role of CYP450 epoxygenase and soluble epoxide hydrolase. Molecular and cellular biochemistry. 2011 350(1-2):101-111.[Abstract ][Full Text ][PDF ]
  118. Li X, Yang G, Zhao G, Wu B, Edin ML, Zeldin DC, Wang DW. Rosuvastatin attenuates the elevation in blood pressure induced by overexpression of human C-reactive protein. Hypertension Research. 2011 34: 869-875.[Abstract ]
  119. Chulada PC, Vainorius E, Garantziotis S, Burch L, Blackshear PJ, Zeldin DC. The Environmental Polymorphism Registry – a unique resource that facilitates translational research of environmental disease. Environmental Health Perspectives. 2011 119(11):1523-1527.[Abstract ]
  120. Edin ML, Wang Z, Bradbury JA, Graves JP, Lih FB, DeGraff LM, Foley JA, Torphy R, Ronnekleiv OK, Tomer KB, Lee CR, Zeldin DC. Endothelial expression of human cytochrome P450 epoxygenase CYP2C8 increases susceptibility to ischemia-reperfusion injury in isolated mouse heart. The FASEB journal. 2011 25(10):3436-3447.[Abstract ][Full Text ]
  121. Chen G, Wang P, Xu G, Gruzdev A, Zeldin DC, Wang DW. Cytochrome P450 Epoxygenase CYP2J2 Attenuates Nephropathy in Streptozotocin-induced Diabetic Mice. Prostaglandins & other lipid mediators. 2011 96(1-4):63-71.[Abstract ]
  122. Panigraphy D, Greene ER, Pozzi A, Wang DW, Zeldin DC. Epoxyeicosatrienoic acid signaling in cancer. Cancer and Metastasis Reviews. 2011 30(3-4):525-540.
  123. Liu L, Chen C, Gong W, Li Y, Edin ML, Zeldin DC, Wang DW. Epoxyeicosatrienoic acids attenuate reactive oxygen species level, mitochrondrial dysfunction, caspase activation and apoptosis in carcinoma cells treated with arsenic trioxide. Journal of Pharmacology and Experimental Therapeutics. In Press, 2011.[Abstract ]
  124. Uehara S, Murayama N, Nakanish Y, Zeldin DC, Yamazaki H, Uno Y. Immunochemical detection of cytochrome P450 enzymes in liver microsomes of 27 cynomolgus monkeys. Journal of Pharmacology and Experimental Therapeutics. 2011 339(2):654-661.[Abstract ]
  125. Li R, Xu X, Chen C, Yu X, Edin ML, DeGraff LM, Lee CR, Zeldin DC, Wang DW. Cytochrome P450 2J2 is protective against global cerebral ischemia in transgenic mice. Prostaglandins & other lipid mediators 2012 99(3-4):68-78.[Abstract ]
  126. Graves JP, Edin ML, Bradbury JA, Gruzdev A, Cheng J , Lih FB , Masinde TA, Qu W, Clayton NP, Morrison JP, Tomer KB, Zeldin DC. Characterization of Four New Mouse Cytochrome P450 Enzymes of the CYP2J Subfamily. Drug metabolism and disposition: the biological fate of chemicals 2013 41(4):763-773.[Abstract ]
  127. Chaudhary KR, Zordoky BN, Edin ML, Alsaleh N, El-Kadi AO, Zeldin DC, Seubert JM. Differential effects of soluble epoxide hydrolase inhibition and CYP2J2 overexpression on postischemic cardiac function in aged mice. Prostaglandins & other lipid mediators. 2013 104-105:8-17.[Abstract ]
  128. Wang X, Ni L, Yang L, Duan Q, Chen C, Edin ML, Zeldin DC, Wang DW. CYP2J2-Derived Epoxyeicosatrienoic Acids Suppress Endoplasmic Reticulum Stress in Heart Failure. Journal of lipid research 2014 85(1):105-115.[Abstract ]
  129. Cheng J, Edin ML, Hoopes SL, Li H, Bradbury JA, Graves JP, DeGraff LM, Lih FB, Garcia V, Shaik JS, Tomer KB, Flake GP, Falck JR, Lee CR, Poloyac SM, Schwartzman ML, Zeldin DC. Vascular characterization of mice with endothelial expression of cytochrome P450 4F2. FASEB journal: official publication of the Federation of American Societies for Experimental Biology 2014 28(7):2915-2931.[Abstract ]


Back to top Back to top

COX-derived Eicosanoids

  1. Boyle JE, Lindroos PM, Rice AB, Zhang L, Zeldin DC, Bonner JC. Prostaglandin-E2 counteracts interleukin-1 stimulated up-regulation of platelet-derived growth factor -receptor on rat pulmonary myofibroblasts. Am J Respir Cell Mol Biol. 1999 Mar;20(3):433-40.[Abstract ][Full Text ][PDF ]
  2. Gavett SH, Madison SL, Chulada P, Scarborough PE, Qu W, Boyle JE, Tiano H, Lee CA, Langenbach R, Roggli V, Zeldin DC. Allergic lung responses are increased in PGH synthase deficient mice. J Clin Invest. 1999 Sep;104(6):721-32.[Abstract ][Full Text ][PDF ]
  3. Bonner JC, Rice A, Bradbury JA, Chulada PC, Moomaw C, Morgan D, Nyska A, Tiano HF, Zeldin DC, Langenbach R. Susceptibility of cyclooxygenase-2-deficient mice to pulmonary fibrogenesis. Am J Pathol. 2002 Aug;161(2):459-70.[Abstract ]
  4. Zeldin DC, Wohlford-Lenane C, Chulada P, Bradbury JA, Scarborough PE, Roggli V, Langenbach R, Schwartz DA. Airway inflammation and responsiveness in prostaglandin H synthase-deficient mice exposed to bacterial lipopolysaccharide. Am J Resp Cell Mol Biol. 2001 Oct;25(4):457-65.[Abstract ][Full Text ][PDF ]
  5. Fritsche E, Baek SJ, King LM, Zeldin DC, Eling TE, Bell DA. Functional characterization of COX-2 polymorphisms. J Pharmacol Exp Therap. 2001 Nov 1;299(2): 468-76.[Abstract ][Full Text ][PDF ]
  6. Camitta MGW, Gabel SA, Chulada PC, Bradbury AJ, Langenbach R, Zeldin DC, Murphy E. Cyclooxygenase-1 and -2 knockout mice demonstrate increased cardiac ischemia/reperfusion injury, but are protected by acute preconditioning. Circulation. 2001 Nov 13;104(20):2453-8.[Abstract ][Full Text ][PDF ]
  7. Zeldin DC. The 5-lipoxygenase pathway: A new therapeutic target for the treatment of pulmonary fibrosis. Am Rev Resp Crit Care Med. 2002 Jan 15;165(2):146-7.[Full Text ][PDF ]
  8. Carey MA, Germolec DR, Bradbury JA, Gooch RA, Moorman MP, Flake GP, Langenbach R, Zeldin DC. Accentuated T helper type 2 airway response after allergen challenge in cyclooxygenase-1-/- but not cyclooxygenase-2 -/- mice. Am J Respir Crit Care Med. 2003 Jun 1;167(11):1509-15.[Abstract ][Full Text ][PDF ]
  9. Carey MA, Germolec DR, Bradbury JA, Gooch RA, Moorman MP, Flake GP, Langenbach R, Zeldin DC. Accentuated Th2 airway response after allergen challenge in COX-1-/- but not COX-2-/- mice. Am J Respir Crit Care Med. 2003 Jun 1;167(11):1509-15.[Abstract ][Full Text ][PDF ]
  10. Carey M, Germolec D, Langenbach R, Zeldin DC. Cyclooxygenase enzymes in allergic inflammation and asthma. Prostaglandins Leukot Essent Fatty Acids. 2003 Aug-Sep;69(2-3):157-62.[Full Text ][PDF ]
  11. Carey MA, Bradbury JA, Langenbach R, Zeldin DC, Germolec DR. Contrasting effects of cyclooxygenase-1 (COX-1) and COX-2 deficiency on the host response to influenza A viral infection. J Immunol. 2005 Nov 15;175(10):6878-6884.[Abstract ][Full Text ][PDF ]
  12. Card JW, Carey MA, Bradbury JA, Graves JP, Lih FB, Moorman MP, Morgan DL, DeGraff LM, Zhao Y, Foley JF, Zeldin DC. Cyclooxygenase-1 overexpression decreases basal airway responsiveness but not allergic inflammation. J Immunol. 2006 Oct 1;177(7):4785-93.[Abstract ][Full Text ][PDF ]
  13. Lee CR, Bottone FG, Krahn J, Li L, Cook ME, Petrovich RM, Mohrenweiser H, Eling TE, Zeldin DC. Identification and functional characterization of polymorphisms in human cyclooxygenase-1 (PTGS1). Pharmacogenet Genomics. 2007 Feb;17(2):145-60.[Abstract ][Full Text ][PDF ]
  14. Card JW, Voltz JW, Carey MA, Bradbury JA, DeGraff LM, Lih FB, Bonner JC, Morgan DL, Flake GP, Zeldin DC. Cyclooxygenase-2 deficiency exacerbates bleomycin-induced lung dysfunction but not fibrosis. Am J Respir Cell Mol Biol. 2007 Sep;37(3):300-8.[Abstract ][Full Text ][PDF ]
  15. Lee CR, North KE, Bray MS, Couper DJ, Heiss G, Zeldin DC. Cyclooxygenase polymorphisms and risk of cardiovascular events: the Atherosclerosis Risk in Communities (ARIC) study. Clin Pharmacol Ther. 2008 Jan;83(1):52-60.[Abstract ][Full Text ][PDF ]
  16. Chung WC, Ryu SH, Sun H, Zeldin DC, Koo JS. CREB mediates prostaglandin F2alpha-induced MUC5AC overexpression. J Immunol. 2009 Feb 15;182(4):2349-56.[Abstract ][Full Text ][PDF ]
  17. Bonner JC, Card JW, Zeldin DC. Nanoparticle-mediated drug delivery and pulmonary hypertension. Hypertension. 2009 May;53(5):751-3.[Abstract ][Full Text ][PDF ]
  18. Card JW, Carey MA, Voltz JW, Bradbury JA, Ferguson CD, Cohen EA, Schwartz S, Flake GP, Morgan DL, Arbes SJ, Barrow DA, Barros SP, Offenbacher S, Zeldin DC. Modulation of allergic airway inflammation by the oral pathogen. Infect Immun. 2010 Jun;78(6):2488-96.[Abstract ][Full Text ][PDF ]
  19. Thomas AC, Driehuys B, Voltz JW, Fubara B, Bradbury JA, Zeldin DC. Ventilation defects observed with hyperpolarized 3He magnetic resonance imaging in a mouse model of acute lung injury. Am J Respir Cell Mol Biol. 2010 Jul 1.[Abstract ][PDF ]
  20. Carey MS, Bradbury JA, Rebolloso YD, Graves JP, Zeldin DC, Germolec DR. Pharmacologic inhibition of COX-1 and COX-2 in influenza A viral infection. PLoS One. 2010 Jul 15;5(7):e11610.[Abstract ][Full Text ][PDF ]
  21. Li H, Bradbury JA, Dackor RT, Edin ML, Graves JP, DeGraff LM, Wang PM, Bortner CD, Maruoka S, Lih FB, Cook DN, Tomer K, Jetten AM, Zeldin DC. Cyclooxygenase-2 (COX-2) regulates Th17 cell differentiation during allergic lung inflammation. Am J Respir Crit Care Med. 2011 184:37-49.[Abstract ][Full Text ][PDF ]
  22. Dackor RT, Cheng J, Voltz JW, Card JW, Ferguson CW, Garrett RC, Bradbury JA, DeGraff LM, Lih FB, Tomer KB, Flake GP, Travlos GS, Ramsey RW Jr, Edin ML, Morgan DL , Zeldin DC. Prostaglandin E2 Protects Murine Lungs from Bleomycin-Induced Pulmonary Fibrosis and Lung Dysfunction. American journal of physiology. Lung cellular and molecular physiology. 2011 301(5):L645-655.[Abstract ]
  23. Spector AA, Campbell WB, Zeldin DC. Introduction. Prostaglandins & other lipid mediators 2011 96(1-4):1-2.[Abstract ]
  24. Panigrahy D, Edin ML, Lee CR, Huang S, Bielenberg DR, Butterfield CE, Barnes CM, Mammoto A, Mammoto T, Luria A, Benny O, Chaponis DM, Dudley AC, Greene ER, Vergilio JA, Pietramaggiori G, Scherer-Pietramaggiori SS, Short SM, Seth M, Lih FB, Tomer KB, Yang J, Schwendener RA, Hammock BD, Falck JR, Manthati VL, Ingber DE, Kaipainen A, D'Amore PA, Kieran MW , Zeldin DC. Epoxy-eicosanoids stimulate multi-organ metastasi and tumor dormancy escape in mice. The Journal of clinical investigation 122(1):178-91, 2012.[Abstract ]
  25. Li H, Edin ML, Bradbury JA, Graves JP, DeGraff LM, Gruzdev A, Cheng J, Dackor RT, Wang PM, Bortner CD, Garantziotis S, Jetten AM, Zeldin DC. Cyclooxygenase-2 Inhibits T Helper Cell Type 9 Differentiation during Allergic Lung Inflammation via Down-regulation of IL-17RB. American journal of respiratory and critical care medicine 2013 187(8):812-822.[Abstract ]


Back to top Back to top

Sex Differences in Lung Response

  1. Card JW, Carey MA, Bradbury JA, DeGraff LM, Morgan DL, Moorman MP, Flake GP, Zeldin DC. Gender differences in murine airway responsiveness and lipopolysaccharide-induced inflammation. J Immunol. 2006 Jul 1;177(1):621-30.[Abstract ][Full Text ][PDF ]
  2. Carey MA, Card JW, Bradbury JA, Moorman MP, Haykal-Coates N, Gavett SH, Graves JP, Walker VR, Flake GP, Voltz JW, Zhu D, Jacobs ER, Dakhama A, Larsen GL, Loader JE, Gelfand EW, Germolec DR, Korach KS, Zeldin DC. Spontaneous airway hyperresponsiveness in estrogen receptor-a deficient mice. Am J Respir Crit Care Med. 2007 Jan 15;175(2):126-35.[Abstract ][Full Text ][PDF ]
  3. Card JW, Voltz JW, Ferguson CD, Carey MA, DeGraff LM, Peddada SD, Morgan DL, Zeldin DC. Male sex hormones promote vagally-mediated reflex airway responsiveness to cholinergic stimulation. Am J Physiol Lung Cell Mol Physiol. 2007 Apr;292(4):L908-14.[Abstract ][Full Text ][PDF ]
  4. Carey MA, Card JW, Voltz JW, Jacobs ER, Dakhama A, Larsen G, Gelfand EW, Zeldin DC. Airway responsiveness should be a measurement of the responsiveness of airways – Reply. Am J Respir Crit Care Med. 2007 Jul 15;176(2):215-16.[Full Text ][PDF ]
  5. Carey MA, Card JW, Voltz JW, Germolec DR, Korach KS, Zeldin DC. The impact of sex and sex hormones on lung physiology and disease: Lessons from animal studies. Am J Physiol Lung Cell Mol Physiol. 2007 Aug;293(2):L272-8.[Abstract ][Full Text ][PDF ]
  6. Carey MA, Card JW, Voltz JW, Arbes SJ Jr, Germolec DR, Korach KS, Zeldin DC. It's all about sex: Male-female differences in lung development and disease. Trends Endocrinol Metab. 2007 Oct;18(8):308-13.[Abstract ][Full Text ][PDF ]
  7. Zeldin DC, Card JW, Carey MA, Voltz JA. Lung impedance measurements are/are not more useful than simpler measurements of lung function in animal models of pulmonary disease. J Appl Physiol. 2007 Nov;103(5):1906; author reply 1909-10.[Full Text ][PDF ]
  8. Voltz JW, Card JW, Carey MA, DeGraff LM, Ferguson CD, Flake GP, Bonner JC, Korach KS, Zeldin DC. Male sex hormones exacerbate lung function impairment after bleomycin-induced pulmonary fibrosis. Am J Respir Cell Mol Biol. 2008 Jul;39(1):45-52.[Abstract ][Full Text ][PDF ]
  9. Card JW, Zeldin DC, Bonner JC, Nestmann ER. Pulmonary applications and toxicity of engineered nanoparticles. Am J Physiol Lung Cell Mol Physiol. 2008 Sep;295(3):L400-11.[Abstract ][Full Text ]
  10. Card JW, Zeldin DC. Hormonal influences on lung function and response to environmental agents: Lessons from animal models of respiratory disease. Proc Am Thorac Soc. 2009 Dec 1;6(7):588-95.[Abstract ][Full Text ][PDF ]
  11. Card JW, Carey MA, Voltz JW, Bradbury JA, Ferguson CD, Cohen EA, Schwartz S, Flake GP, Morgan DL, Arbes SA, Barrow DA, Barros SP, Offenbacher S, Zeldin DC. Modulation of allergic airway inflammation by the oral pathogen porphyromonas gingivalis. Infect Immun. 2010 Jun;78(6):2488-96.[Abstract ][Full Text ][PDF ]


Back to top Back to top

Allergen Exposure and Intervention

  1. Vojta PJ, Randels S, Stout J, Muilenberg M, Burge H, Mitchell H, O'Conner G, Zeldin DC. Effects of physical interventions on house dust mite allergen levels in carpet, bed, and upholstery dust in low-income, urban homes. Environ Health Perspect. 2001 Aug;109(8): 815-9.[Abstract ][Full Text ][PDF ]
  2. Vojta PJ, Friedman W, Marker D, Clickner R, Rogers JW, Viet SM, Muilenberg ML, Burge HA, Thorne PS, Arbes SJ, Zeldin DC. First National Survey of Lead and Allergens in Housing: survey design and methods for the allergen and endotoxin components. Environ Health Perspect. 2002 May;110(5):527-32.[Abstract ][Full Text ][PDF ]
  3. Jacobs DE, Clickner RP, Zhou JY, Viet SM, Marker DA, Rogers JW, Zeldin DC, Broene P, Friedman W. The prevalence of lead-based paint hazards in U.S. housing. Environ Health Perspect. 2002 Oct;110(10):A599-606.[Abstract ][Full Text ][PDF ]
  4. Arbes SJ, Sever M, Archer J, Long EH, Gore C, Schal C, Walter M, Neubler B, Vaughn B, Mitchell H, Liu E, Collette N, Adler P, Sandel M, Zeldin D.C. Abatement of cockroach allergen (Bla g 1) in low-income, urban housing: A randomized control trial. J Allergy Clin Immunol. 2003 Aug;112(2):339-45.[Abstract ][Full Text ][PDF ]
  5. Arbes SJ, Cohn R, Yin M, Muilenberg ML, Burge HA, Friedman W, Zeldin DC. House dust mite allergens in U.S. beds: Results from the First National Survey of Lead and Allergens in Housing. J Allergy Clin Immunol. 2003 Feb;111(2):408-14.[Abstract ][Full Text ][PDF ]
  6. Chulada PC, Arbes SJ, Dunson D, Zeldin DC. Breast-feeding and the prevalence of asthma and wheeze in children: Analyses from the Third National Health and Nutrition Examination Survey, 1988-1994. J Allergy Clin Immunol. 2003 Feb;111(2):328-36.[Abstract ][Full Text ][PDF ]
  7. Chulada PC, Arbes SJ Jr., Zeldin DC. Breast-feeding, passive smoking, and asthma and wheeze in children, J Allergy Clin Immunol. 2003 112:808-809.[Full Text ][PDF ]
  8. Arbes SJ, Sever M, Mehta J, Gore JC, Schal C, Vaughn B, Mitchell H, Zeldin DC. Abatement of cockroach allergens (Bla g 1 and Bla g 2) in low-income, urban housing: Month 12 continuation results. J Allergy Clin Immunol. 2004 Jan;113(1):109-14.[Abstract ][Full Text ][PDF ]
  9. Chulada PC, Carey MA, Zeldin DC. Fatty acids in breast milk promote immune development and protect against atopic disease. J Allergy Clin Immunol. 2004:113(5);1002-1003.[Full Text ][PDF ]
  10. Cohn RD, Arbes SJ, Yin M, Jaramillo R, Zeldin DC. National prevalence of mouse allergen in U.S. households. J Allergy Clin Immunol. 2004 Jun;113(6):1167-71.[Abstract ][Full Text ][PDF ]
  11. Arbes SJ, Cohn R, Yin M, Muilenberg ML, Burge HA, Friedman W, Zeldin DC. Dog allergen (Can f 1) and cat allergen (Fel d 1) in U.S. homes: Results from the National Survey of Lead and Allergens in Housing. J Allergy Clin Immunol. 2004 Jul;114(1):111-7.[Abstract ][Full Text ][PDF ]
  12. Salo PM, Yin M, Arbes SJ, Cohn RD, Sever M, Muilenberg M, Burge HA, London SJ, Zeldin DC. Dustborn alternaria alternata antigens in U.S. homes: Results from the First National Survey of Lead and Allergens in Housing. J Allergy Clin Immunol. 2005 Sep;116(3):623-9.[Abstract ][Full Text ]
  13. Resnick DB, Sharp R, Zeldin DC. Research on environmental health interventions: ethical problems and solutions. Account Res. 2005 Apr-Jun;12(2):69-101.[Abstract ]
  14. Arbes SJ, Sever M, Vaughn B, Mehta J, Lynch JT, Mitchell H, Hoppin JA, Spencer HL, Sandler DP, Zeldin DC. Feasibility of using subject-collected dust samples in epidemiologic and clinical studies of indoor allergens. Environ Health Perspect. 2005 Jun;113(6):665-9.[Abstract ][Full Text ][PDF ]
  15. Arbes SJ, Sever M, Mehta J, Collette N, Thomas B, Zeldin DC. Exposure to indoor allergens in day care facilities: Results from two North Carolina counties. J Allergy Clin Immunol. 2005 Jul;116(1):133-139.[Abstract ][PDF ]
  16. Arbes SJ, Gergen PJ, Elliott L, Zeldin DC. Prevalences of positive skin test responses to 10 common allergens in the U.S. population: Results from the Third National Health and Nutrition Examination Survey. J Allergy Clin Immunol. 2005 Aug;116(2):377-83.[Abstract ][Full Text ][PDF ]
  17. Pate A, Hamilton RG, Ashley PJ, Zeldin DC, Halsey JF. Proficiency testing of allergen measurements in residential dust. J Allergy Clin Immunol. 2005 Oct;116(4):844-50.[Abstract ][Full Text ][PDF ]
  18. Thorne PS, Kulhankova K, Yin M, Cohn R, Arbes S, Zeldin DC. Endotoxin Exposure is a risk factor for asthma. The National Survey of Endotoxin in U.S. Housing. Am J Respir Crit Care Med. 2005 Dec 1;172(11):1371-7. 2005 Sep 1.[Abstract ][Full Text ][PDF ]
  19. Cohn RD, Arbes SJ, Jaramillo R, Reid LH, Zeldin DC. National prevalence and exposure risk for cockroach allergen (Bla g 1) in U.S. households: Results from the National Survey of Lead and Allergens in Housing. Environ Health Perspect. 2006 Apr;114(4):522-6.[Abstract ][Full Text ][PDF ]
  20. Zeldin DC, Eggleston P, Chapman M, Piedimonte G, Renz H, Peden D. How exposures to biologics influence the induction and incidence of asthma. Environ Health Perspect. 2006 Apr;114(4):620-6.[Abstract ][Full Text ][PDF ]
  21. Salo, P.M., Arbes, S.J., Cohn, R.D., Burge, H.A., London, S.J. and Zeldin, D.C. Alternaria alternata antigens in U.S. homes. J Allergy Clin Immunol. 2006 Feb;117(2):473; author reply 474.[Abstract ][Full Text ][PDF ]
  22. Barnes C, Portnoy J, Sever M, Arbes SJ, Vaughn B, Zeldin DC. Comparison of enzyme immunoassay-based assays for environmental alternaria alternata. Ann Allergy Asthma Immunol. 2006 Sep;97(3):350-6.[Abstract ][Full Text ][PDF ]
  23. Thorne PS, Arbes SJ, Zeldin DC. Endotoxin and asthma. Am J Respir Crit Care Med. 2006 May 15;173(10):1177.[Full Text ][PDF ]
  24. Arbes SJ, Sever ML, Vaughn B, Cohen EA, Zeldin DC. Oral pathogens and allergic disease: Results from the Third National Health and Nutrition Examination Survey. J Allergy Clin Immunol. 2006 Nov;118(5):1169-75. Epub 2006 Sep 12.[Abstract ][Full Text ][PDF ]
  25. Salo PM, Arbes SJ, Sever M, Jaramillo R, Cohn RD, London SJ, Zeldin DC. Exposure to alternaria alternata in us homes is associated with asthma symptoms. J Allergy Clin Immunol. 2006 Oct;118(4):892-8.[Abstract ][Full Text ][PDF ]
  26. Elliott L, Arbes SJ, Harvey ES, Lee RC, Salo PM, Cohn RD, London SJ, Zeldin DC. Dust weight and asthma prevalence in the National Survey of Lead and Allergens in Housing (NSLAH). Environ Health Perspect. 2007 Feb;115(2):215-20. Epub 2006 Nov 7.[Abstract ][Full Text ][PDF ]
  27. Sever ML, Arbes SJ, Gore C, Santangelo RG, Vaughn B, Mitchell H, Schal C, Zeldin DC. Cockroach allergen reduction by cockroach control alone in low-income, urban homes-A randomized control trial. J Allergy Clin Immunol. 2007 Oct;120(4):849-55. Epub 2007 Sep 7.[Abstract ][Full Text ][PDF ]
  28. Arbes SJ, Gergen PJ, Vaughn B, Zeldin DC. Asthma cases attributable to atopy: results from the Third National Health and Nutrition Examination Survey. J Allergy Clin Immunol. 2007 Nov;120(5):1139-45. 2007 Sep 24.[Abstract ][Full Text ][PDF ]
  29. Salo PM, Arbes SJ, Crockett PW, Thorne PS, Cohn RD, Zeldin DC. Exposure to multiple indoor allergens in US homes and relationship to asthma. J Allergy Clin Immunol. 2008 Mar;121(3):678-684.e2. 2008 Feb 6.[Abstract ][Full Text ][PDF ]
  30. Resnik D, Zeldin D. Environmental health research on hazards in the home and the duty to warn. Bioethics 2008 May;22(4):209-217.[Abstract ][Full Text ][PDF ]
  31. Gergen PJ, Arbes SJ, Vaughn B, Zeldin DC. Self-reported, doctor-diagnosed "asthma" is not necessarily asthma: Reply. J Allergy Clin Immunol. 2008 May;121(5):1291.[Abstract ]
  32. Visness CM, London SJ, Daniels JL, Kaufman JS, Yeatts KB, Siega-Riz AM, Liu AH, Calatroni A, Zeldin DC. Association of obesity with IgE levels and allergy symptoms in children and adolescents: Results from National Health and Nutrition Examination Survey 2005-2006. J Allergy Clin Immunol. 2009 May;123(5):1163-9, 1169.e1-4. 2009 Feb 23.[Abstract ][Full Text ][PDF ]
  33. Salo PM, Jaramillo R, Cohn RD, London SJ, Zeldin DC. Exposure to mouse allergen in US homes is associated with asthma symptoms. Environ Health Perspect. 2009 Mar;117(3):387-91. 2008 Oct 6.[Abstract ][Full Text ][PDF ]
  34. Thorne PS, Cohn R, Arbes SJ, Zeldin DC. Predictors of Endotoxin Levels in U.S. Housing. Environ Health Perspect. 2009 May;117(5):763-71. 2008 Oct 16.[Abstract ][Full Text ][PDF ]
  35. Salo PM, Sever ML, Zeldin DC. Indoor allergens in school and day-care environments. J Allergy Clin Immunol. 2009 Aug;124(2):185-92, 192.e1-9; quiz 193-4. 2009 Jul 3.[Abstract ][Full Text ][PDF ]
  36. Gergen PJ, Arbes SJ, Calatroni A, Mitchell HE, Zeldin DC. Total IgE and asthma prevalence in the U.S. population: Results from the National Health and Nutrition Examination Survey (NHANES) 2005-2006. J Allergy Clin Immunol. 2009 Sep;124(3):447-53. 2009 Aug 3.[Abstract ][Full Text ][PDF ]
  37. Fessler MB, Massing MW, Spruell B, Jaramillo R, Draper DW, Madenspacher JH, Arbes SJ, Calatroni A, Zeldin DC. Novel relationship of serum cholesterol with asthma and wheeze in the United States. J Allergy Clin Immunol. 2009 Nov;124(5):967-74.e1-15. 2009 Oct 3.[Abstract ]
  38. Salo PM, Zeldin DC. Does exposure to cats and dogs decrease the risk of developing allergic sensitization and disease? J Allergy Clin Immunol. 2009 Oct;124(4):751-2.[Abstract ][Full Text ][PDF ]
  39. Fessler MB, Jaramillo R, Crockett PW, Zeldin DC. Relationship of serum cholesterol levels to atopy in the U.S. population. Allergy. 2010 Jul;65(7):859-64. 2009 Dec 16.[Abstract ][Full Text ][PDF ]
  40. Salo PM, Zeldin DC. Reply: Cats and dogs, an attractive remedy versus atopy. J Allergy Clin Immunol. 2010 Mar;125(3):765-6.[Full Text ][PDF ]
  41. Krieger J, Jacobs DE, Ashley PJ, Bzaeder A, Chew GL, Dearborn D, Hynes HP, Miller JD, Morley R, Rabito F, Zeldin DC. Housing interventions and control of asthma-related indoor biologic agents: A review of the evidence. J Public Health Manag Pract. 2010 Sep-Oct;16(5 Suppl):S11-20.[Abstract ][Full Text ][PDF ]
  42. Visness CM, London SJ, Daniels JL, Kaufman JS, Yeatts KB, Siega-Riz AM, Calatroni A, Zeldin DC. Association of Childhood Obesity with Atopic and Non-Atopic Asthma: Results from the National Health and Nutrition Examination Survey 1999-2006. J Asthma. 2010 47(7):822-829.[Abstract ][Full Text ][PDF ]
  43. Liu AH, Jaramillo R., Sicherer SH, Wood RA, Bock SA, Burks AW, Massing M, Cohn RD, Zeldin DC. National Prevalence and Risk Factors for Food Allergy and Relationship to Asthma: Results from the National Health and Nutrition Examination Survey 2005-2006. J Allergy Clin Immunol. 2010 126: 798-806.[Abstract ]
  44. Salo PM, Calatroni A, Gergen PJ, Hoppin JA, Sever ML, Jaramillo R, Arbes SJ, Zeldin DC. Allergy-related outcomes in relation to serum IgE: Results from the National Health and Nutrition Examination Survey 2005-2006. J Allergy Clin Immunol. 2011 127(5):1226-1235.e7.[Abstract ]
  45. Hoppin JA, Jaramillo R, Salo P, Sandler DP, London SJ, Zeldin DC. Questionnaire predictors of atopy in a U.S. population sample: Findings from the National Health and Nutrition Examination Survey, 2005-2006. Am J Epidemiol. 2011 173:544-552.[Abstract ]
  46. Sever ML, Salo PM, Haynes AK, Zeldin DC. Inner-city environments and mitigation of cockroach allergen. Am J Prev Med. 2011 41:S55-56.[Full Text ]
  47. Satoh M, Chan EK, Ho LA, Rose KM, Parks CG, Cohn RD, Jusko TA, Walker NJ, Germolec DR, Whitt IZ, Crockett PW, Pauley BA, Chan JY, Ross SJ, Birnbaum LS, Zeldin DC, Miller FW. Prevalence and Sociodemographic Correlates of Anti-nuclear Antibodies In the United States. Arthritis and rheumatism 2012 64(7):2319-27.[Abstract ]
  48. Wilson RH, Maruoka S , Whitehead GS, Foley JF , Flake GP, Sever ML, Zeldin DC, Kraft M , Garantziotis S, Nakano H, Cook DN. The Toll-like receptor 5 ligand flagellin promotes asthma by priming allergic responses to indoor allergens. Nature medicine. 2012  18(11):1705-10.[Abstract ]
  49. Chaudhary KR, King EM, Filep S, Smith B, Platts-Mills T, Hamilton RG, Schmechel D, Sordillo JE, Milton D, van Ree R, Krop EJ, Heederik DJ, Metwali N, Thorne PS, Zeldin DC, Sever ML, Calatroni A, Arbes SJ Jr, Mitchell HE, Chapman MD. A multi-center ring trial of allergen analysis using fluorescent multiplex array technology. J Immunol Methods. 2013 387(1-2):89-95.[Abstract ]
  50. Weir CH, Yeatts KB, Sarnat JA, Vizuete W, Salo PM, Jaramillo R, Cohn RD, Chu H, Zeldin DC, London SJ. Nitrogen dioxide and allergic sensitization in the 2005-2006 National Health and Nutrition Examination Survey. Respir Med. 2013 107(11):1763-72.[Abstract ]
  51. Hoppin JA, Jaramillo R, London SJ, Bertelsen RJ, Salo PM, Sandler DP , Zeldin DC. Phthalate exposure and allergy in the U.S. population: results from NHANES 2005-2006. Environmental health perspectives 2013 121(10):1129-1134.[Abstract ]
  52. Hoppin JA, Umbach DM, Long S, Rinsky JL, Henneberger PK, Salo PM, Zeldin DC, London SJ, Alavanja MC, Blair A, Beane Freeman LE, Sandler DP. Respiratory disease in United States farmers. Occupational and environmental medicine. 2014 71(7):484-491.[Abstract ]


Back to top Back to top

Back to Top